Key Highlights

  • Kazia Therapeutics shares settled down 19% at $13.64.
  • The company priced a public offering of ADSs and warrants that can raise up to $80 million gross if fully exercised.
  • Proceeds are earmarked for oncology programs, including Stage 4 triple-negative breast cancer readouts in the second half of 2027.
  • HR+/HER2- breast cancer data is expected in the first half of 2028.

Kazia Therapeutics Limited (NASDAQ: KZIA) shares settled down 19% at $13.64 after the company priced a public offering of ADSs and warrants that can raise up to $80 million gross if Series A and B warrants are fully exercised.

What Happened

Base proceeds from the offering will be smaller than the full $80 million figure, which depends on future Warrant exercise. Proceeds are earmarked to fund the pipeline, including Stage 4 triple-negative breast cancer readouts in the second half of 2027 and HR+/HER2- breast cancer data in the first half of 2028, related to paxalisib and other oncology programs.

Market Reaction

Shares fell as investors weighed the dilution implied by the offering structure, with warrant-heavy financings often pricing in additional potential share issuance whenever conditions allow the warrants to be exercised.

Outlook

The Stage 4 triple-negative breast cancer readout expected in the second half of 2027, followed by HR+/HER2- breast cancer data in the first half of 2028, represent the next major disclosed clinical milestones funded by this offering.